Generate Biomedicines (NASDAQ:GENB – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.
Earnings and Valuation
This table compares Generate Biomedicines and Monte Rosa Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Generate Biomedicines | $31.89 million | 50.59 | -$203.15 million | ($1.59) | -7.91 |
| Monte Rosa Therapeutics | $123.67 million | 6.43 | -$38.63 million | ($1.40) | -6.65 |
Monte Rosa Therapeutics has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Generate Biomedicines and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Generate Biomedicines | N/A | N/A | N/A |
| Monte Rosa Therapeutics | -186.24% | -30.14% | -20.35% |
Institutional and Insider Ownership
80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings for Generate Biomedicines and Monte Rosa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Generate Biomedicines | 1 | 1 | 6 | 0 | 2.62 |
| Monte Rosa Therapeutics | 1 | 2 | 8 | 1 | 2.75 |
Generate Biomedicines currently has a consensus price target of $26.40, suggesting a potential upside of 110.02%. Monte Rosa Therapeutics has a consensus price target of $26.44, suggesting a potential upside of 184.04%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Generate Biomedicines.
Summary
Monte Rosa Therapeutics beats Generate Biomedicines on 9 of the 13 factors compared between the two stocks.
About Generate Biomedicines
Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.
Receive News & Ratings for Generate Biomedicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generate Biomedicines and related companies with MarketBeat.com's FREE daily email newsletter.
